The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I study of MDM2 antagonist RG7112 in patients (pts) with relapsed/refractory solid tumors.
Razelle Kurzrock
Research Funding - Roche
Jean-Yves Blay
Honoraria - GlaxoSmithKline; Novartis; Pfizer; PharmaMar; Roche
Research Funding - GlaxoSmithKline; Novartis; Pfizer; PharmaMar; Roche
Binh Bui Nguyen
Honoraria - Novartis; PharmaMar
Research Funding - Roche
Andrew J. Wagner
Consultant or Advisory Role - Genentech; Novartis; Pfizer; Sanofi
Research Funding - Genentech; Lilly; Novartis; Pfizer; Roche
Robert G. Maki
Research Funding - Roche
Gary K. Schwartz
Research Funding - Roche
Amita Patnaik
Research Funding - Roche
Lia Gore
Research Funding - Roche
Lin Wu
Employment or Leadership Position - Roche
Stock Ownership - Roche
Lyubomir T Vassilev
Employment or Leadership Position - Roche
Stock Ownership - Roche
Michelle Ding
Employment or Leadership Position - Roche
Stock Ownership - Roche
David Geho
Employment or Leadership Position - Roche
Stock Ownership - Roche
Jianguo Zhi
Employment or Leadership Position - Roche
Stock Ownership - Roche
Steven Middleton
Employment or Leadership Position - Roche
Stock Ownership - Roche
Gwen L. Nichols
Employment or Leadership Position - Roche
Stock Ownership - Roche